Sartorius, DE0006292006

Sartorius stock eases after TecDAX rally on fresh analyst support

Published on 09/16/2026 at 17:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius stock trades around EUR 237 on Xetra on September 16, 2026, after a 4.7 percent gain in the previous TecDAX session. Analysts now see an average price target of about EUR 276, adding support despite recent volatility.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius AG stock (ISIN DE0006292006) is trading around EUR 237 on Xetra on September 16, 2026, following a strong move in the previous session that lifted the shares by about 4.7 percent within the TecDAX index.

Recent price action and index role

According to Investing.com on September 15, 2026, Sartorius AG preferred shares rose 4.70 percent to EUR 238.60, making them one of the top performers in both the MDAX and TecDAX.

A separate overview from Finanzen.net shows that on September 16, 2026, the Sartorius preferred share was quoted at EUR 237.30 in Xetra trading, down about 0.5 percent intraday with a day low at EUR 236.30.

Analyst targets provide medium-term orientation

Analyst coverage summarized by Finanzen.net on September 16, 2026 indicates an average price target of EUR 276.44 for Sartorius preferred stock, implying an upside of roughly 16.5 percent relative to the indicated Xetra level of EUR 237.30.

In the same analyst table, ratings from several houses are listed as of recent weeks, including Buy recommendations from Berenberg and UBS, Overweight from Barclays, and Sector Perform from RBC, underlining that the stock remains actively followed with a range of views on risk and reward.

Fundamental backdrop from recent year

A sector overview of cell therapy technology companies published by MarketGrowthReports on September 16, 2026 notes that Sartorius generated revenue of USD 3.7 billion (about EUR 3.4 billion) in the past year and operates over 60 manufacturing and sales sites worldwide.

For investors, the combination of a global manufacturing footprint and exposure to bioprocessing equipment and reagents, as highlighted in that overview, provides a structural demand story that complements the more volatile short-term price movements.

Stock level and investor takeaways

With Sartorius stock changing hands at roughly EUR 237 on Xetra as of September 16, 2026, the shares trade below the average analyst target of EUR 276.44 derived from recent coverage, while still reflecting the strong 4.70 percent gain recorded on September 15, 2026 in MDAX and TecDAX trading.